Hepatitis C treatment and alopecia totalis

Area of Science:

• Hepatology
• Dermatology
• Immunology

Background:

• Pegylated interferon alpha-2a/2b and ribavirin are primary treatments for chronic hepatitis C.
• Cutaneous side effects are known but alopecia areata is rarely reported.
• Alopecia areata's pathophysiology remains incompletely understood.

Observation:

• A patient developed alopecia universalis shortly after completing chronic hepatitis C treatment.
• The patient received pegylated interferon and ribavirin therapy.
• Alopecia universalis is a severe form of alopecia areata involving complete body hair loss.

Findings:

• The case presents a rare instance of alopecia universalis linked to hepatitis C treatment.
• This adverse event highlights a potential connection between antiviral therapy and autoimmune hair loss.
• The temporal association suggests a possible role for the treatment in triggering or exacerbating alopecia areata.

Implications:

• This case contributes to the understanding of alopecia areata's diverse triggers.
• It suggests that hepatitis C treatments may influence autoimmune responses affecting hair follicles.
• Further research is warranted to explore the mechanisms linking antiviral therapies to alopecia areata.